Navigation Links
HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
Date:9/4/2007

- Collaborative studies will use HistoRx AQUA(R)-based assays to evaluate clinical utility of protein biomarkers for predicting treatment response

and outcome in brain tumors -

NEW HAVEN, Conn., Sept. 4 /PRNewswire/ -- HistoRx, Inc., announced today that it has entered into a research collaboration with the Radiation Therapy Oncology Group (RTOG), a National Cancer Institute-funded clinical cooperative group. Under the terms of the agreement, HistoRx will provide RTOG researchers access to HistoRx's AQUA(R) technology for biomarker analysis and will develop customized immunohistochemical assays to be used by RTOG in investigating the relationship between specific protein biomarkers and clinical responsiveness in brain tumor patients. HistoRx intends to commercialize assays and reagents developed in the course of the collaboration for clinical use as predictive diagnostics.

The RTOG studies will use a combination of high-throughput tissue microarrays, multiplex analysis, and AQUA(R) analysis-based assays to determine whether brain tumor patients are likely to respond to a specific targeted therapy and whether the biomarkers under investigation may be used to predict survival.

"We selected HistoRx's AQUA(R) technology based on its unique ability to measure protein biomarker expression and localization in diseased tissue sections in a precisely quantitative, reproducible, and standardized way," said Arnab Chakravarti, MD, of Massachusetts General Hospital and a member of the RTOG Translational Research Program. "By eliminating the subjective interpretation inherent in conventional qualitative immunohistochemical analysis, we expect this collaboration will provide a substantial boost to our research in brain cancer by enabling RTOG researchers to reveal stronger, more reliable statistical correlations linking protein biomarker expression with prediction of patient response to therapy and disease outcome."

"As the relationship between protein expression patterns and disease gains an expanding role in new drug and diagnostic development and in the way physicians treat patients and individualize therapeutic regimens, we continue to advance our goal of replacing conventional immunohistochemistry with AQUA(R) analysis, a more precise and consistent tool that is enabling pathologists and clinicians to integrate data from predictive biomarker studies confidently into research, diagnosis, and patient treatment," said Rana K. Gupta, CEO of HistoRx. "We are pleased to have reached this agreement with such a renowned organization as The Radiation Therapy Oncology Group and to have its endorsement of the AQUA(R) technology's predictive power and potential for developing companion diagnostic and prognostic assays."

About HistoRx (http://www.historx.com)

HistoRx is a systems pathology company developing and commercializing quantitative biomarker analysis technology that provides exceptional measurement and localization of proteins in their natural context within tissue. The pioneering HistoRx proprietary AQUA(R) (Automated Quantitative Analysis) technology is the first platform capable of measuring biomarker concentration with subcellular resolution to generate more precise, efficient answers about the safety and effectiveness of new therapeutics in development and to enable development of companion diagnostic tests for targeted therapies. HistoRx services are used by pharmaceutical and biotechnology companies throughout the drug discovery, preclinical study, and clinical development continuum. HistoRx has two lines of diagnostic products in development: HistoRx companion diagnostic products are linked to partners' drug candidates in development to predict prognostic outcome; and HistoRx is independently developing AQUA(R)-based diagnostics for the clinical diagnosis, prognosis, and treatment management of complex diseases.

About RTOG

The Radiation Therapy Oncology Group (RTOG) is a clinical research enterprise of the American College of Radiology (ACR), located in the ACR Philadelphia, PA office. RTOG is a multi-institutional international clinical cooperative group funded primarily by the National Cancer Institute. RTOG has over 35 years of experience in conducting clinical trials and is comprised of over 280 major research institutions in the United States and Canada. The group currently is conducting more than 40 active studies that involve radiation therapy alone or in conjunction with surgery and/or chemotherapeutic drugs or which investigate quality of life issues and their effects on the cancer patient.

CONTACT: Mary Moynihan

M2Friend Biocommunications

(802) 951-9600

mary@m2friend.com


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
2. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
3. Viventia biotech reports synergystic effect of its Proxinium antibody in combinaton with chemotherapy and radiation
4. Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival Benefits as Mitigator Against Radiation-Induced Damage in Study
5. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
6. Hollis-Eden Announces Cancellation of Acute Radiation Syndrome RFP by Department of Health and Human Services
7. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
8. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
9. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
10. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
11. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2018)... and DALLAS (PRWEB) , ... September 21, 2018 ... ... HRE professionals need to stay “ahead of the curve” and understand how the ... Real Estate Conference will be held Sept. 26-27 at the Westin Galleria Dallas ...
(Date:9/15/2018)... YORK (PRWEB) , ... September 14, 2018 , ... ... of “Rare Diseases." This campaign showcases the innovative work being done within rare ... future therapies for those living with rare diseases. , The ...
(Date:9/15/2018)... , ... September 14, 2018 , ... ... to benefit individuals and families affected by Hurricane Florence. , Throughout the month ... financial donations in any amount, or round up their transaction to the nearest ...
Breaking Medicine Technology:
(Date:9/24/2018)... ... September 24, 2018 , ... Smile Brands Inc . was named ... Year and People-Focused CEO of the Year in the third annual Stevie Awards for ... and the human resources professionals, teams, achievements and HR-related products and suppliers who help ...
(Date:9/24/2018)... TAMPA, Fla. (PRWEB) , ... September 24, 2018 , ... ... – invites all to rise up for a faster cure during Childhood Cancer Awareness ... with a future of uncertainty. Cancer is the number one cause of death by ...
(Date:9/23/2018)... ... September 23, 2018 , ... ... small business and non-profit organizations, announced today their selection as an approved ... Technical Assistance (TA) Program and the TA Marketplace in the ...
(Date:9/22/2018)... , ... September 22, 2018 , ... The health risks ... serious health risk that particularly affects older adults – the risk of injury due ... second of the day and adult aged 65 and older falls in the United ...
(Date:9/15/2018)... ... September 14, 2018 , ... ... other funding, full FY 2019 appropriations for Labor, Health and Human Services and ... the evidence-based Teen Pregnancy Prevention (TPP) Program, and $286.5 million for the Title ...
Breaking Medicine News(10 mins):